KLRS vs. RAPT, CCCC, TNYA, TIL, SXTC, IMRX, NVCT, DERM, ACTU, and CRBU
Should you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Rapt Therapeutics (RAPT), C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), Instil Bio (TIL), China SXT Pharmaceuticals (SXTC), Immuneering (IMRX), Nuvectis Pharma (NVCT), Journey Medical (DERM), Actuate Therapeutics (ACTU), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry.
Kalaris Therapeutics vs. Its Competitors
Kalaris Therapeutics (NASDAQ:KLRS) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
Rapt Therapeutics' return on equity of -67.92% beat Kalaris Therapeutics' return on equity.
Kalaris Therapeutics currently has a consensus target price of $3.00, suggesting a potential downside of 30.07%. Rapt Therapeutics has a consensus target price of $21.57, suggesting a potential upside of 88.61%. Given Rapt Therapeutics' higher probable upside, analysts plainly believe Rapt Therapeutics is more favorable than Kalaris Therapeutics.
Kalaris Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500.
66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 75.0% of Kalaris Therapeutics shares are held by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Kalaris Therapeutics had 4 more articles in the media than Rapt Therapeutics. MarketBeat recorded 4 mentions for Kalaris Therapeutics and 0 mentions for Rapt Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.20 beat Rapt Therapeutics' score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media.
Summary
Kalaris Therapeutics beats Rapt Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Kalaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kalaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KLRS) was last updated on 9/4/2025 by MarketBeat.com Staff
Free KLRS Stock Alerts